Circulating lymphocytes in HNSCC display coordinated expression of selected senescence-associated genes, with IL-6 and CXCL1 as candidate prognostic biomarkers linked to tumor progression that warrant further validation.
Key Findings
Results
LMNB1 was significantly upregulated in all three lymphocyte subsets (CD4+, CD8+, and CD19+) of HNSCC patients compared to controls.
LMNB1 upregulation was observed across all circulating lymphocyte subsets studied
The study included 58 HNSCC patients at baseline and 13 controls
LMNB1 is a classical marker of cellular senescence whose downregulation is typically associated with senescent cells, making upregulation in this context a notable finding
Expression was measured by RT-qPCR in sorted lymphocytes
Results
IL-6, CXCL1, and IL-1β were elevated in CD4+ T cells of HNSCC patients.
These three SASP-related cytokines/chemokines showed elevated expression specifically in the CD4+ T cell subset
Expression was measured by RT-qPCR in flow-sorted peripheral blood lymphocytes
The cohort consisted of 58 HNSCC patients at baseline compared to 13 controls
TNFα was also measured but was not reported among the elevated markers in CD4+ cells
Results
A coordinated co-expression network involving IL-6, CXCL1, IL-1β, P16INK4a/CDKN2A, and LMNB1 was observed in circulating lymphocytes of HNSCC patients.
The co-expression pattern suggests coordinated regulation of senescence-associated genes across lymphocyte subsets
The network included both SASP factors (IL-6, CXCL1, IL-1β) and canonical senescence markers (P16INK4a/CDKN2A, LMNB1)
Correlation analyses were used to identify these co-expression relationships
This coordinated pattern was observed in peripheral CD4+, CD8+, and CD19+ cells
Results
IL-6 expression in CD8+ T cells was associated with higher nodal stage and worse survival in HNSCC patients.
Higher nodal stage (more advanced lymph node involvement) was linked to elevated IL-6 in CD8+ T cells
Survival analyses included Kaplan-Meier curves and Cox regression modeling
This association positions IL-6 in CD8+ T cells as a candidate prognostic biomarker for tumor progression
The baseline cohort comprised 58 HNSCC patients with survival follow-up
Results
CXCL1 expression in CD19+ B cells independently predicted survival in HNSCC patients.
CXCL1 in CD19+ B cells was identified as an independent predictor of survival via Cox regression analysis
This finding suggests B cell-derived SASP signaling may have prognostic relevance in HNSCC
CXCL1 is a chemokine involved in neutrophil recruitment and is considered a canonical SASP factor
The independent predictive value was established after accounting for other variables in the multivariate model
Results
No significant differences in senescence-associated gene expression were found between pre-treatment and post-treatment samples.
31 patients had post-treatment samples available for comparison
58 patients were assessed at baseline (pre-treatment)
The absence of treatment-induced changes was observed across the measured genes: IL-6, IL-1β, TNFα, CXCL1, P16INK4a/CDKN2A, and LMNB1
Nonparametric statistical tests were used for these comparisons
Methods
The study systematically evaluated SASP-related genes and senescence markers in sorted peripheral lymphocyte subsets from HNSCC patients for the first time.
Six genes were measured: IL-6, IL-1β, TNFα, CXCL1, P16INK4a/CDKN2A, and LMNB1
Three lymphocyte subsets were analyzed: CD4+ T cells, CD8+ T cells, and CD19+ B cells
Flow cytometric sorting was used to isolate lymphocyte subsets prior to RT-qPCR analysis
The study included 58 HNSCC patients at baseline, 31 post-treatment, and 13 healthy controls
Statistical analyses included nonparametric tests, correlation analyses, Kaplan-Meier survival analysis, and Cox regression
What This Means
This research suggests that immune cells circulating in the blood of head and neck cancer (HNSCC) patients show signs of a biological aging process called cellular senescence, in which cells stop dividing normally but remain metabolically active and secrete inflammatory molecules. The researchers measured six genes linked to this process in three types of immune cells — CD4+ T helper cells, CD8+ killer T cells, and CD19+ B cells — collected from 58 cancer patients before treatment, 31 patients after treatment, and 13 healthy individuals. They found that LMNB1 (a structural protein whose changes are a hallmark of senescence) was elevated across all immune cell types in cancer patients, and that inflammatory signaling molecules IL-6, CXCL1, and IL-1β were particularly elevated in CD4+ T cells. These molecules appeared to be co-regulated together, suggesting a coordinated senescence-associated response in circulating immune cells.
The study also found clinically meaningful associations: patients whose CD8+ killer T cells had higher IL-6 expression tended to have more advanced lymph node involvement and worse survival outcomes. Additionally, CXCL1 levels in CD19+ B cells independently predicted survival, meaning this marker may carry prognostic information beyond what is captured by standard clinical factors. Notably, treatment did not appear to change the expression of these senescence-associated genes, suggesting the patterns observed reflect a stable biological state rather than a transient response.
This research suggests that measuring senescence-related gene activity in circulating immune cells could provide useful information about cancer progression and patient prognosis in HNSCC. IL-6 in CD8+ T cells and CXCL1 in B cells emerged as the most promising candidate biomarkers. However, the authors note that these findings require validation in larger studies before any clinical application could be considered, and that the role of immune cell senescence in cancer biology remains an active area of investigation.